These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 1645555)

  • 1. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
    Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
    Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S; Riou G
    Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
    Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
    J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
    Multon E; Riou JF; LeFevre D; Ahomadegbe JC; Riou G
    Biochem Pharmacol; 1989 Jul; 38(13):2077-86. PubMed ID: 2544183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC; Ashorn CL; Chan D; Zwelling LA
    Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.
    Pommier Y; Minford JK; Schwartz RE; Zwelling LA; Kohn KW
    Biochemistry; 1985 Nov; 24(23):6410-6. PubMed ID: 3002440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
    Bakic M; Beran M; Andersson BS; Silberman L; Estey E; Zwelling LA
    Biochem Biophys Res Commun; 1986 Jan; 134(2):638-45. PubMed ID: 3004458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
    Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
    Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
    Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
    Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
    Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity.
    Estey E; Adlakha RC; Hittelman WN; Zwelling LA
    Biochemistry; 1987 Jul; 26(14):4338-44. PubMed ID: 2822085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
    Riou JF; Grondard L; Petitgenet O; Abitbol M; Lavelle F
    Biochem Pharmacol; 1993 Sep; 46(5):851-61. PubMed ID: 8396937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B; Riou JF; Lavelle F; Pommier Y
    Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further characterization of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target.
    Mayes J; Hinds M; Soares L; Altschuler E; Kim P; Zwelling LA
    Biochem Pharmacol; 1993 Aug; 46(4):699-707. PubMed ID: 8395843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.